vs

Side-by-side financial comparison of Arq, Inc. (ARQ) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $29.4M, roughly 1.2× Arq, Inc.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 8.8%). Arq, Inc. produced more free cash flow last quarter ($-3.5M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 16.4%).

Arq, Inc. is a sustainable technology firm focused on processing coal mining waste to produce high-value, low-carbon solid fuels and industrial carbon products. It caters to customers across the energy, construction, and manufacturing sectors, with core markets in North America and major European regions, aiming to cut industrial waste and carbon footprints for its clients.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ARQ vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.2× larger
RXRX
$35.5M
$29.4M
ARQ
Growing faster (revenue YoY)
RXRX
RXRX
+672.9% gap
RXRX
681.7%
8.8%
ARQ
More free cash flow
ARQ
ARQ
$43.8M more FCF
ARQ
$-3.5M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
16.4%
ARQ

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARQ
ARQ
RXRX
RXRX
Revenue
$29.4M
$35.5M
Net Profit
$-108.1M
Gross Margin
13.6%
59.8%
Operating Margin
-174.1%
-304.8%
Net Margin
-304.2%
Revenue YoY
8.8%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$-1.20
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQ
ARQ
RXRX
RXRX
Q4 25
$29.4M
$35.5M
Q3 25
$35.1M
$5.2M
Q2 25
$28.6M
$19.2M
Q1 25
$27.2M
$14.7M
Q4 24
$27.0M
$4.5M
Q3 24
$34.8M
$26.1M
Q2 24
$25.4M
$14.4M
Q1 24
$21.7M
$13.8M
Net Profit
ARQ
ARQ
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-653.0K
$-162.3M
Q2 25
$-2.1M
$-171.9M
Q1 25
$203.0K
$-202.5M
Q4 24
$-178.9M
Q3 24
$1.6M
$-95.8M
Q2 24
$-2.0M
$-97.5M
Q1 24
$-3.4M
$-91.4M
Gross Margin
ARQ
ARQ
RXRX
RXRX
Q4 25
13.6%
59.8%
Q3 25
28.8%
-183.8%
Q2 25
33.3%
-4.9%
Q1 25
36.4%
-48.0%
Q4 24
36.3%
-181.4%
Q3 24
38.6%
53.7%
Q2 24
32.2%
36.2%
Q1 24
36.9%
19.1%
Operating Margin
ARQ
ARQ
RXRX
RXRX
Q4 25
-174.1%
-304.8%
Q3 25
-2.4%
-3327.6%
Q2 25
-5.4%
-916.8%
Q1 25
2.4%
-1297.9%
Q4 24
1.5%
-4042.4%
Q3 24
5.8%
-377.1%
Q2 24
-5.6%
-697.4%
Q1 24
-13.7%
-698.4%
Net Margin
ARQ
ARQ
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-1.9%
-3135.3%
Q2 25
-7.5%
-894.2%
Q1 25
0.7%
-1373.3%
Q4 24
-3935.5%
Q3 24
4.7%
-367.5%
Q2 24
-7.7%
-676.6%
Q1 24
-15.7%
-662.4%
EPS (diluted)
ARQ
ARQ
RXRX
RXRX
Q4 25
$-1.20
$-0.17
Q3 25
$-0.02
$-0.36
Q2 25
$-0.05
$-0.41
Q1 25
$0.00
$-0.50
Q4 24
$-0.03
$-0.56
Q3 24
$0.04
$-0.34
Q2 24
$-0.06
$-0.40
Q1 24
$-0.09
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQ
ARQ
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$6.6M
$743.3M
Total DebtLower is stronger
$28.7M
$9.6M
Stockholders' EquityBook value
$168.0M
$1.1B
Total Assets
$230.6M
$1.5B
Debt / EquityLower = less leverage
0.17×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQ
ARQ
RXRX
RXRX
Q4 25
$6.6M
$743.3M
Q3 25
$7.0M
$659.8M
Q2 25
$7.0M
$525.1M
Q1 25
$6.3M
$500.5M
Q4 24
$13.5M
$594.4M
Q3 24
$48.7M
$427.6M
Q2 24
$28.5M
$474.3M
Q1 24
$35.2M
$296.3M
Total Debt
ARQ
ARQ
RXRX
RXRX
Q4 25
$28.7M
$9.6M
Q3 25
$26.1M
$11.9M
Q2 25
$28.9M
$14.2M
Q1 25
$27.1M
$16.4M
Q4 24
$25.1M
$19.0M
Q3 24
$21.6M
$20.5M
Q2 24
$22.2M
$22.9M
Q1 24
$22.6M
Stockholders' Equity
ARQ
ARQ
RXRX
RXRX
Q4 25
$168.0M
$1.1B
Q3 25
$217.2M
$1.0B
Q2 25
$216.8M
$919.1M
Q1 25
$218.2M
$933.9M
Q4 24
$217.3M
$1.0B
Q3 24
$218.1M
$524.6M
Q2 24
$189.6M
$584.4M
Q1 24
$175.2M
$401.2M
Total Assets
ARQ
ARQ
RXRX
RXRX
Q4 25
$230.6M
$1.5B
Q3 25
$277.9M
$1.4B
Q2 25
$284.5M
$1.3B
Q1 25
$283.7M
$1.3B
Q4 24
$284.4M
$1.4B
Q3 24
$280.0M
$726.5M
Q2 24
$248.6M
$775.9M
Q1 24
$229.8M
$557.8M
Debt / Equity
ARQ
ARQ
RXRX
RXRX
Q4 25
0.17×
0.01×
Q3 25
0.12×
0.01×
Q2 25
0.13×
0.02×
Q1 25
0.12×
0.02×
Q4 24
0.12×
0.02×
Q3 24
0.10×
0.04×
Q2 24
0.12×
0.04×
Q1 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQ
ARQ
RXRX
RXRX
Operating Cash FlowLast quarter
$-2.8M
$-46.1M
Free Cash FlowOCF − Capex
$-3.5M
$-47.3M
FCF MarginFCF / Revenue
-12.0%
-133.1%
Capex IntensityCapex / Revenue
2.7%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-11.3M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQ
ARQ
RXRX
RXRX
Q4 25
$-2.8M
$-46.1M
Q3 25
$5.3M
$-117.4M
Q2 25
$527.0K
$-76.4M
Q1 25
$-5.8M
$-132.0M
Q4 24
$5.2M
$-115.4M
Q3 24
$7.7M
$-59.2M
Q2 24
$-3.0M
$-82.2M
Q1 24
$526.0K
$-102.3M
Free Cash Flow
ARQ
ARQ
RXRX
RXRX
Q4 25
$-3.5M
$-47.3M
Q3 25
$3.1M
$-117.6M
Q2 25
$-1.4M
$-79.6M
Q1 25
$-9.5M
$-133.8M
Q4 24
$-37.8M
$-116.7M
Q3 24
$-5.8M
$-63.8M
Q2 24
$-22.1M
$-83.4M
Q1 24
$-9.1M
$-109.0M
FCF Margin
ARQ
ARQ
RXRX
RXRX
Q4 25
-12.0%
-133.1%
Q3 25
8.8%
-2272.5%
Q2 25
-4.7%
-413.9%
Q1 25
-34.9%
-907.4%
Q4 24
-139.6%
-2567.7%
Q3 24
-16.5%
-244.6%
Q2 24
-87.1%
-578.5%
Q1 24
-41.7%
-789.9%
Capex Intensity
ARQ
ARQ
RXRX
RXRX
Q4 25
2.7%
3.5%
Q3 25
6.3%
4.7%
Q2 25
6.6%
16.4%
Q1 25
13.6%
12.4%
Q4 24
158.9%
28.6%
Q3 24
38.7%
17.5%
Q2 24
75.5%
8.2%
Q1 24
44.1%
48.2%
Cash Conversion
ARQ
ARQ
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
-28.59×
Q4 24
Q3 24
4.76×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons